TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23575046
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% (0.5 ml) prior to fentanyl 150 μg (3 ml)
Study: 19721169
Drug: Intracapsular injection
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracapsular injection of 8 ml of 2% lidocaine
Study: 17961836
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (group NSI)
Study: 17961836
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate infusion (group RLI)
Study: 9025819
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group - CTL)
Study: 1497157
Drug: Meperidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (75 mg)
Study: 6206687
Drug: Metrizamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrizamide (300 mg I/ml)
Study: 27489241
Drug: Anti-NKG2D (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-NKG2D (2 mg/kg, single subcutaneous dose)
Study: 26241597
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction therapy (n=58)
Study: 26241597
Drug: Present-centered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered group therapy (n=58)
Study: 23508680
Drug: Psychosocial and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial and/or pharmacotherapy (sertraline)
Study: 21644308
Drug: Gaitianli (Oyster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaitianli (Oyster Shell and Calcium Carbonate Chewable) tablets
Study: 10232502
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg, increased to 160 mg after 4 weeks)
Study: 10232502
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg, increased to 100 mg after 4 weeks)
Study: 8674154
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of dolasetron (1.8 mg/kg)
Study: 8674154
Drug: Multiple-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose regimen of dolasetron (0.6 mg/kg each, total 1.8 mg/kg)
Study: 1855018
Drug: Steroid with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid with distension
Study: 1855018
Drug: Steroid only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid only
Study: 6411441
Drug: Dobutamine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (7 micrograms/kg . min) + Nitroglycerin (1.5-3.0 mg/h)
Study: 6411441
Drug: Nitroglycerin (3.0-6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (3.0-6.0 mg/h)
Study: 6411441
Drug: Nitroglycerin (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (increased dose)
Study: 31541008
Drug: Two-level, variable-volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-level, variable-volume epidural blood patch (EBP)
Study: 26743587
Drug: Polypill (containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (containing aspirin 75 mg, simvastatin 20 mg, lisinopril 10 mg and hydrochlorothiazide 12.5 mg)
Study: 23080351
Drug: Liposome bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome bupivacaine 89 mg
Study: 23080351
Drug: Liposome bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome bupivacaine 155 mg
Study: 23080351
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 50 mg
Study: 20206430
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg weekly during the second half of the cycle)
Study: 20206430
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg daily during the second half of the cycle)
Study: 10334140
Drug: Fluticasone at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone at 4 mg via MDI spacer
Study: 10334140
Drug: Fluticasone at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone at 2 mg via MDI spacer
Study: 10334140
Drug: Budesonide at
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide at 4 mg via MDI spacer
Study: 10334140
Drug: Budesonide at
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide at 2 mg via MDI spacer
Study: 10334140
Drug: Beclomethasone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone at 4 mg via MDI spacer
Study: 26083771
Drug: Creatine loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine loading (20 g·d⁻¹ for 5 days)
Study: 21809733
Drug: Kangaroo care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo care (KC) and live harp music therapy
Study: 17284748
Drug: Synbiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic preparation (SYN1 + Lactobacillus rhamnosus GG + Bifidobacterium lactis Bb12)
Study: 15462618
Drug: Confidence-accuracy calibration
Normalized name: Phisoderm Clear Confidence Body Wash
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidence-accuracy calibration for sequential mini-lineups
Study: 9725476
Drug: Test formulations
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulations (two new formulations)
Study: 9725476
Drug: Test capsule
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test capsule
Study: 25387843
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of vancomycin (1 mg/0.1 ml)
Study: 25387843
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of cefuroxime (1 mg/0.1 ml)
Study: 18642209
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) combined with intravitreal injection of bevacizumab (1.25 mg)
Study: 18642209
Drug: Standard photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard photodynamic therapy (PDT)
Study: 8669166
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/week in association with Ursodeoxycholic acid (UDCA) 500 mg/day
Study: 31550251
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Suicide Prevention therapy
Study: 23099329
Drug: NDV-3 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDV-3 (30 μg Als3p)
Study: 23099329
Drug: NDV-3 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDV-3 (300 μg Als3p)
Study: 15736118
Drug: acarbose (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: acarbose (150 mg/d)
Study: 15736118
Drug: voglibose (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.9 mg/d)
Study: 15736118
Drug: voglibose (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.3 mg)
Study: 11756072
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) containing 56 mg isoflavones (ISP56)
Study: 11756072
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein (ISP) containing 90 mg isoflavones (ISP90)
Study: 2515527
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 micrograms daily)
Study: 2515527
Drug: De‐Nol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: De‐Nol (5 ml four times a day diluted with 15 ml of water)
Study: 30595326
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg
Study: 30595326
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg
Study: 23918588
Drug: Resveratrol (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (3g daily for 12 weeks)
Study: 2286438
Drug: Steam therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam therapy in a cloth tent (Study Group)
Study: 2286438
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steam therapy)
Study: 26343332
Drug: RED-D (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: RED-D (modified brief Cognitive Behavioral Therapy delivered telephonically by a mental health professional)
Study: 25208663
Drug: 380 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 380 g of farmed Atlantic salmon fillets per week for 15 weeks
Study: 25208663
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g of salmon oil per week for 15 weeks
Study: 19963031
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (9 g daily for 12 weeks)
Study: 17496286
Drug: PCI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI treatment of re-infarction
Study: 17496286
Drug: Regional differences
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional differences in treatment
Study: 12004808
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine (1 mg x m(‐1)) and ketamine (0.75 mg x m(‐1)) via PCAS
Study: 12004808
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg x m(‐1)) via PCAS
Study: 2189149
Drug: High-dose alternate-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alternate-day prednisolone
Study: 7322959
Drug: Indapamide, 2.5
Normalized name: Indapamide, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide, 2.5 mg daily
Study: 7322959
Drug: Cyclopenthiazide, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclopenthiazide, 0.5 mg daily
Study: 31694568
Drug: ROTEM®-guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROTEM®-guided treatment in patients with long CPB-times (> 115 min.; n = 55)
Study: 24048773
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg orally twice daily for 3 days
Study: 24048773
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice daily for 3 days
Study: 19533304
Drug: Intravenous moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moderate doses of human recombinant Epo (epoietin-alpha, 100 or 200 IU/kg/die)
Study: 31580316
Drug: FITÂ® Lady
Approvals — FDA: no, EMA: no, PMDA: no
Description: FITÂ® Lady patch (active patch)
Study: 28987358
Drug: Fermented plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented plant extract (FPE) 60 mL
Study: 21871686
Drug: Saxagliptin 5mg
Normalized name: Saxagliptin 5mg Oral tablet
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin 5mg daily plus metformin
Study: 18974285
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/day and Olmesartan 40 mg/day administered separately for 10 days
Study: 18974285
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of Amlodipine/Olmesartan 10 mg/40 mg
Study: 18974285
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet taken 30 minutes after a high-fat breakfast
Study: 18974285
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 10 mg to 40 mg with Amlodipine 5 mg to 10 mg
Study: 17102570
Drug: Colestimide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestimide (3 g/day)
Study: 14767300
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg controlled release melatonin at night
Study: 31923074
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (5%) applied at least 10 minutes before biopsy
Study: 31923074
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection (1%) administered at least 1 minute prior to biopsy
Study: 31923074
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (5%)
Study: 31923074
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection (1%)
Study: 29299888
Drug: Pudendal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal nerve block (PDB-Group) with 0.3 ml/kg 0.25% bupivacaine
Study: 29299888
Drug: Penile nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile nerve block (PNB-Group) with 0.3 ml/kg 0.25% bupivacaine
Study: 11094866
Drug: Nicotrol NS
Normalized name: Nicotrol NS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotrol NS (3 mg nicotine)
Study: 1317765
Drug: L-tryptophan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (2 g)
Study: 20099987
Drug: Ziprasidone 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 320 mg/day
Study: 20099987
Drug: Haloperidol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2.5 mg/day
Study: 20099987
Drug: Haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 15 mg/day
Study: 8275889
Drug: Haloperidol 30
Normalized name: Haloperidol 300 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 30 mg/day
Study: 19026036
Drug: Midostaurin 25
Normalized name: midostaurin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 25 mg twice daily
Study: 19026036
Drug: Midostaurin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 50 mg twice daily
Study: 19026036
Drug: Midostaurin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 75 mg twice daily
Study: 16189072
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) 800 mg/day
Study: 12925463
Drug: Acetylcholine (ACh;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born at term (n=19)
Study: 12925463
Drug: Acetylcholine (ACh;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born preterm (n=35)
Study: 8263271
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g table salt)
Study: 8263271
Drug: Sucrose capsule
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose capsule (1 g sucrose)
Study: 8263271
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2000 mg)
Study: 24731521
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (2 g over 20 minutes)
Study: 24731521
Drug: Nebulised magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised magnesium sulphate (3 × 500 mg over 1 hour)
Study: 24731521
Drug: Placebo (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard therapy alone)
Study: 24731521
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate vs Placebo
Study: 21152828
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Trifolium pratense, 1 capsule/day
Study: 21152828
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules containing lactose, 1 capsule/day
Study: 18257183
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Prostat Tablets)
Study: 12637480
Drug: Intravenous irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous irinotecan (40 to 125 mg/m2 every 2 weeks) plus oral ciclosporin (5 mg/kg bid for 3 days)
Study: 12637480
Drug: Intravenous irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous irinotecan
Study: 10533946
Drug: Education intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Education intervention on antibiotic use
Study: 7368972
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment after onset of symptoms
Study: 6098034
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g im) plus daily placebo injections with probenicid (1 g orally)
Study: 6098034
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g im on each of three days) plus probenicid (1 g orally)
Study: 6098034
Drug: Single-dose cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cefotaxime (1 g im) plus probenicid (1 g orally)
Study: 23160441
Drug: Daily lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lens replacement each morning
Study: 23160441
Drug: Monthly lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly lens replacement (historical control)
Study: 15809409
Drug: Continuation medication
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation medication
Study: 1451927
Drug: Sultamicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sultamicillin (50 mg/kg in two equal doses each day for a mean of 10 days)
Study: 1451927
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg in three equal doses each day for a mean of 11 days)
Study: 30808022
Drug: GDNF (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDNF (120 μg per putamen)
Study: 27093771
Drug: Sodium perborate
Normalized name: Sodium Perborate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium perborate solution for 5 minutes per day combined with brushing
Study: 27093771
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine digluconate solution for 5 minutes per day combined with brushing
Study: 25410068
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia (7.5 mg hypobaric bupivacaine)
Study: 25410068
Drug: Bilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral spinal anesthesia (12 mg hypobaric bupivacaine)
Study: 18319308
Drug: Estrogen-progestin treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin treatment (EPT)
Study: 15944847
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg o.d.)
Study: 15944847
Drug: Amoxicillin-clavulanate (1,000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (1,000/125 mg t.i.d.) plus roxithromycin (150 mg b.i.d.)
Study: 12866746
Drug: Diane 35
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane 35 plus CPA (cyproterone acetate [2 mg] and ethinyl estradiol [35 microg])
Study: 12866746
Drug: Diane 35
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane 35 plus spironolactone [100 mg]
Study: 12866746
Drug: Spironolactone [100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone [100 mg] alone
Study: 23168373
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (8 g CHO per kg body mass)
Study: 23168373
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (3 g CHO per kg body mass)
Study: 20880596
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 30 mg kg(‐1) in saline (20 mL)
Study: 18854793
Drug: Lidocaine +
Normalized name: Lidocaine + Menthol Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine + Ketorolac (30 mg)
Study: 18854793
Drug: Lidocaine +
Normalized name: Lidocaine + Menthol Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine + Ketorolac (30 mg) + Dexamethasone (8 mg)
Study: 18854793
Drug: Lidocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (3 mg x kg‐1)
Study: 1814322
Drug: Oestradiol (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (4, 2, or 1 mg) + Norethisterone acetate (1 mg)
Study: 1814322
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (2 mg) + Cyproterone acetate (1 mg) + Calcium (1000 mg)
Study: 6359851
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 to 240 mg)
Study: 6359851
Drug: Bendroflumethiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (5 to 10 mg)
Study: 6359851
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bendroflumethiazide and Nadolol (B + N)
Study: 28992526
Drug: Pharmacogenetics-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetics-guided treatment
Study: 26559142
Drug: Laser‐1st treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser‐1st treatment (Selective laser trabeculoplasty)